Search
Aldeyra Therapeutics Inc
ALDXAdd to Watchlist
1.170USD
-0.120-9.30%
Close 10-02 16:00（ET）
70.57MMarket Cap
LossP/E TTM
Aldeyra Therapeutics Inc (ALDX) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Aldeyra Therapeutics Inc in the past month.
Buy
2 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
7.167USD+512.54%
ALDX Analyst Recommendation Trends
In the current month, ALDX has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALDX average Analyst price target in the last month is 7.167.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2
2
3
3
3
3
3
3
2
2
2
2
2
2
2
3
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
6
6
6
6
6
6
ALDX Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ALDX EPS is projected to reach -0.094 in FY2026Q3, following reported EPS of -0.090 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.17
-0.10
-0.09
-0.09
-0.10
Actual
-0.11
-0.06
-0.09
--
--
Surprise
+36.07%
+41.29%
+3.88%
--
--
FAQs
What is Aldeyra Therapeutics Inc's expected revenue for the next quarter?
Aldeyra Therapeutics Inc's expected revenue is 24.25M.
What is Aldeyra Therapeutics Inc's price target?
Analysts forecast that Aldeyra Therapeutics Inc's price target is USD 7.17, with the highest forecast at USD 13.00 and the lowest forecast at USD 2.00.
How have Aldeyra Therapeutics IncALDX's recent earnings per share performed?
The market expectation was USD -0.09, while Aldeyra Therapeutics IncALDX's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Aldeyra Therapeutics Inc?
Based on the ratings of Aldeyra Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.